Assay development time will be reduced with the introduction of a range of pre-developed protocols for G-protein-coupled receptors (GPCR) membranes
GE Healthcare, a combination of the former Amersham and GE Medical Systems, is to help further address bottlenecks in the drug discovery process with the introduction of a range of pre-developed protocols for G-protein-coupled receptors (GPCR) membranes.
These pre-validated protocols offer substantial time-savings of up to 15 days during the GPCR assay development stage.
The new scintillation proximity assay (SPA) GPCR assays offer researchers working in high throughput screening environments pre-developed assay conditions for GPCR receptor-ligand binding studies.
"GE Healthcare is continually working to help cut development time throughout the drug discovery process," comments John Sutton, vice president product management, cell analysis and screening at GE Healthcare.
"This is the first time that Spa GPCR protocols have been available in this way.
"By providing ready-made optimum assay conditions for GPCR ligand binding studies, GE Healthcare is reducing assay development process time for researchers, therefore enabling them to focus on screening potential drug candidates".
These Spa GPCR assays broaden GE Healthcare's SPA range and comprise Spa beads and radioligands from GE Healthcare with GPCR receptor membranes from Euroscreen, as well as a pre-validated protocol describing the required procedure for the GPCR assay.
